Twist Bioscience Co. (NASDAQ:TWST) Receives $51.90 Consensus PT from Analysts

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) has earned an average recommendation of "Moderate Buy" from the ten analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $51.90.

A number of equities analysts have issued reports on TWST shares. Wolfe Research initiated coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an "outperform" rating and a $60.00 price objective on the stock. Scotiabank lifted their price objective on Twist Bioscience from $50.00 to $54.00 and gave the stock a "sector outperform" rating in a research note on Tuesday, November 19th. TD Cowen reiterated a "buy" rating and issued a $58.00 price objective on shares of Twist Bioscience in a report on Tuesday, November 26th. Leerink Partners raised their target price on Twist Bioscience from $45.00 to $48.00 and gave the stock a "market perform" rating in a report on Thursday, October 17th. Finally, Robert W. Baird upped their price target on Twist Bioscience from $46.00 to $48.00 and gave the company an "outperform" rating in a research note on Tuesday, November 19th.

Twist Bioscience Stock Performance

Twist Bioscience stock traded down $0.50 during trading hours on Wednesday, reaching $45.12. 660,920 shares of the company's stock traded hands, compared to its average volume of 658,584. Twist Bioscience has a fifty-two week low of $27.41 and a fifty-two week high of $60.90. The firm's 50 day moving average is $46.22 and its 200-day moving average is $46.48. The firm has a market capitalization of $2.68 billion, a price-to-earnings ratio of -12.53 and a beta of 1.85.

Insiders Place Their Bets

In other Twist Bioscience news, COO Patrick John Finn sold 2,261 shares of Twist Bioscience stock in a transaction dated Wednesday, October 23rd. The stock was sold at an average price of $43.09, for a total value of $97,426.49. Following the sale, the chief operating officer now owns 159,483 shares of the company's stock, valued at $6,872,122.47. This trade represents a 1.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Dennis Cho sold 659 shares of the business's stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $41.56, for a total value of $27,388.04. Following the completion of the sale, the insider now owns 94,481 shares in the company, valued at approximately $3,926,630.36. This trade represents a 0.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 78,754 shares of company stock worth $3,619,144. Company insiders own 3.92% of the company's stock.

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds have recently made changes to their positions in TWST. Wilmington Savings Fund Society FSB bought a new stake in shares of Twist Bioscience during the 3rd quarter worth approximately $34,000. Signaturefd LLC raised its position in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after acquiring an additional 306 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in Twist Bioscience in the second quarter valued at $61,000. Beaird Harris Wealth Management LLC acquired a new stake in Twist Bioscience in the third quarter valued at $95,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock worth $98,000 after purchasing an additional 381 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.